Junshi and Lilly to File for Emergency Use of Paired Antibodies for COVID-19

Junshi Bio of Shanghai and Lilly released positive interim data on their paired antibody treatment for COVID-19. In early results from a Phase II trial, the combination reduced viral load, symptoms and COVID-related hospitalization and ER visits. Detailed data will be released later in a journal article. Lilly plans to file for Emergency Use Authorization of the combination therapy for patients with mild-to-moderate COVID-19 in November 2020, followed by a BLA filing as early as Q2 2021. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: LLY) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.